Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475696 · ClinicalTrials.gov registry record · Phase 2
Urge Incontinence Bladder Overactivity Study
A Phase 2 study of Urinary Incontinence, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 3
- Study locations
NCT00475696: Completed Phase 2 study of Urinary Incontinence, sponsored by Eli Lilly and Company.
NCT00475696 is a Phase 2 study of Urinary Incontinence that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants, above the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (17% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475696, a Phase 2 study of Urinary Incontinence, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency. Subjects in study will be permitted to escalate or de-escalate between 80 mg/day and 120 mg/day in consultation with the investigator and based on their adverse events.
Conditions Studied
Interventions
- DRUG Duloxetine
Study Locations (3)
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
Queensland
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Townsville
Ontario
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - North York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
What the finished NCT00475696 record still lists
NCT00475696 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 256-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (17% higher).
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Duloxetine is the first listed.
NCT00475696 reports a single indexed study location in Indiana, Queensland, Ontario.
Frequently Asked Questions
What is clinical trial NCT00475696 about?
NCT00475696 is a clinical study titled "Urge Incontinence Bladder Overactivity Study". Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency. Subjects in study will be permitted to escalate or de-escalate between 80 mg/day and 120 mg/day in consultation with the investigator and based on thei...
What is the current status of trial NCT00475696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2002-11. Estimated completion is 2005-03.
What conditions does trial NCT00475696 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT00475696?
The interventions under investigation include: Duloxetine (DRUG).
Who is sponsoring clinical trial NCT00475696?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00475696 being conducted?
This trial has 3 study locations across Indiana, Queensland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00475696's enrollment target sits among peer trials
300 12th of 48 higher than 37 of 48 other Urinary Incontinence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Urinary Incontinence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Examining the Effects of Intra-detrusor Botox at Time of HoLEP in Men With Overactive Bladder Symptoms
RECRUITING · Phase 2
-
Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence
COMPLETED · Phase 2
-
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
COMPLETED · Phase 2
-
Translating Unique Learning for Incontinence Prevention
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia